Join Isogenica at ELRIG: Drug Discovery 2021

Oct 15, 2021

Isogenica is excited to announce its attendance at ELRIG: Drug Discovery  October 19-20th 2021

Isogenica’s Research Scientist, David Knight, will be attending ELRIG: Drug Discovery 2021. 

David will be presenting a poster on the latest Isogenica VHH data on VHH drug discovery using synthetic libraries.

Isogenica uses diverse (1e13) fully synthetic camelid domain antibody (VHH) libraries for internal and partnered drug discovery. Humanised synthetic libraries offer several advantages over immunisation or the use of naïve libraries, including diversity and the speed of clone isolation.

To learn more about the benefits of our synthetic libraries and how these can be applied to your projects, catch David at the conference to start an informal discussion.

If Isogenica VHH antibodies have application in your discovery projects or you would like to learn more about partnering with Isogenica, get in touch and we will be glad to schedule a meeting.

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”

Contact

Mandeep Sehmi,
Business Development

T +44 1799 533 680

E mandeep.sehmi@isogenica.com